Home › Immunoglobulin Light-chain Amyloidosis › Tennessee › Nashville
Immunoglobulin Light-chain Amyloidosis clinical trials in Nashville, TN
3 studies for Immunoglobulin Light-chain Amyloidosis are looking for participants at sites in and around Nashville (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis
RecruitingPhase 2
- GSK Investigational Site, Nashville
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
RecruitingPhase 1/2
- Vanderbilt Ingram Cancer Center, Nashville
A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
RecruitingPhase 1/2
- Research Site, Nashville
Immunoglobulin Light-chain Amyloidosis trials in other cities
- Boston, MA8 studies
- Rochester, MN5 studies
- Durham, NC4 studies
- New York City, NY4 studies
- New Haven, CT3 studies
- Columbus, OH3 studies
- Cleveland, OH3 studies
- Salt Lake City, UT3 studies
Other studies in Nashville
- Non-Small Cell Lung Cancer97 studies
- Breast Cancer78 studies
- Metastatic Cancer69 studies
- Colorectal Cancer67 studies
- Cancer (all types)65 studies
- Ovarian Cancer50 studies
- Head and Neck Squamous Cell Carcinoma43 studies
- Prostate Cancer40 studies
- Pancreatic Cancer39 studies
- Lung Cancer39 studies
- Endometrial Cancer38 studies
- Melanoma34 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.